Overview

A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past. Tabalumab will be given in combination with standard doses of two other drugs that are often used to treat MM. Study doctors will collect information about the effectiveness and side effects of this therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Antibodies, Monoclonal
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate